Novo Nordisk’s Wegovy pill captured more than 80% of new oral obesity prescriptions in the United States, according to company presentations reported by Yahoo News Malaysia.
The pill launched in the U.S. in January 2026. It is now a central part of the strategy for Novo Nordisk to regain market share from Eli Lilly.
Novo Nordisk faces competition in the injectable market. Its injectable Wegovy shares have dropped over 70% from their peak. Lilly surpassed the Danish firm to take the lead in the obesity-drug market.
“There's no denying that Eli Lilly clearly has the lead in the injectable obesity drug market, but Novo has the upper hand when it comes to the pill,” said Lars Hytting, a Copenhagen-based investor at Novo shareholder ArthaScope.
But the rapid uptake of the pill is helping to stabilize the GLP-1 franchise.
“We’ve been able to hold the baton,” Mike Doustdar, CEO, told Reuters. He said he is convinced Eli Lilly “is trying really hard to reverse this thing, and we need to watch them.”

Wegovy patients lose weight
Patients who stayed on the daily Wegovy pill lost an average of 6.2% of their body weight over three months. This data came from new observational results presented at the ObesityWeek conference in Washington, Yahoo News Malaysia reported.
The analysis focused on 5,872 adults using the Ro telehealth platform. These people had no prior experience with weight-loss medication. They also completed the full three-month duration on the pill.
Participants began treatment between January 5 and February 7, 2026. They saw an average weight reduction of 6.3 kg (13.9 pounds). This was from a starting weight of 103.0 kg (227 pounds).
About three-fifths of these users achieved a weight loss of at least 5%. Roughly one in six lost at least 10% of their total weight.
“The real-world data was encouraging as it broadly replicated the findings of 5.5% weight loss at 12 weeks seen in Novo’s late-stage trial for the pill,” said Martin Holst Lange, Novo Nordisk’s Chief Scientific Officer, in an interview with Yahoo News Malaysia.
The company also presented findings regarding “food noise,” or recurring thoughts about food. In the OCTANE analysis, this measure decreased by about 25% over a three-month period among 6,180 pill users, according to company presentations. Researchers noted a methodological caveat regarding selection bias in these findings.
Oral drugs face competition
Oral treatments now represent roughly a third of U.S. obesity prescriptions. The obesity market is moving toward these oral options.
Novo Nordisk holds over 80% of new oral prescriptions. Eli Lilly’s Foundayo (orforglipron) is emerging as a direct competitor.
The Jefferies team estimated Lilly’s share in the oral market at a little more than 26%. Novo holds nearly 74%.

“So we've consistently seen a lower capture rate for Wegovy pill than the competitive oral product,” Novo's EVP of U.S. operations, Jamey Millar, said.
Recent prescription data shows the gap between the two leading oral drugs is narrowing.
| Metric | Novo Wegovy Pill | Lilly Foundayo |
|---|---|---|
| Recent Weekly Prescriptions | ~184,000 | 53,321 |
| U.S. Oral Market Share | >80% of new starts | ~1 in 3 new starts |
| Third-Quarter Sales | Nearly $811 million | $184 million |
Novo raises its outlook
Novo Nordisk has raised its 2026 outlook for the third time this year. The company expects adjusted sales and operating profit growth to range from a 2% decline to a 2% increase at constant exchange rates (CER), Yahoo Finance reported.
The Wegovy pill makes up about 6% of expected sales. It is expected to play a major role in this recovery.
The pill generated DKK 5.4 billion in global sales during the third quarter of 2026. Novo plans to expand the pill to more than 20 markets in 2027. It has already launched in eight markets as of early November.

The pill holds about 90% of the UK oral obesity market. It holds 80% in the UAE.
Novo faces technical and competitive hurdles. Anton Kharitonov, Traders Union expert, said Novo Nordisk stock has been under selling pressure. It trades below the H1 SMA-20 at $39.66 and the D1 SMA-200 at $42.9.
This struggle for dominance comes as Novo Nordisk maintains its position as the largest pharmaceutical company in Denmark. The Danish multinational, which was created in 1989 through the merger of two companies dating back to the 1920s, achieved a market capitalization in 2023 that exceeded the GDP of Denmark. It also became the highest valued company in Europe.
Novo is also pursuing growth outside of obesity. The company filed for approval of Etavopivat with the FDA and EMA. It also announced a joint venture with AI firm nference on November 18, 2026, to develop solutions for obesity, diabetes, and heart disease.